Study authors assessed if switching to bictegravir/emtricitabine/tenofovir alafenamide in patients older than the age of 50 years could help lower drug-drug interactions, maintain virologic suppression, and lower lipids.
Study authors sought to determine the necessity of antiretroviral laboratory monitoring, particularly for hepatic, renal, and lipid testing, in people with HIV younger than 40 years of age during the era of COVID-19.
Investigators compared the prevalence of HIV among patients hospitalized with COVID-19 compared to the general population and sought to determine whether patients with HIV had higher susceptibility to COVID-19.
